SAFI BIOTHERAPEUTICS received a $4.7 million deferred grant from the US Department of Defense Advanced Research Projects Agency to advance the first clinical trial of artificial red blood cells.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.